ELVN CMO sells 5,000 shares, exercises options
Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins reported both stock sales and an option exercise in the company’s shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins reported both stock sales and an option exercise in the company’s shares. On May 18, 2026, she sold a total of 5,000 shares of Common Stock in open-market transactions at prices including $39.5340, $40.2473 and $41.2052 per share.
On the same date, she exercised a stock option to acquire 5,000 shares of Common Stock at an exercise price of $2.4800 per share. Following these transactions, she directly owned 25,000 shares of Common Stock and held 126,268 stock options exercisable at $2.4800 per share, expiring on June 17, 2031. The filing notes that the option exercise and related sales were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 5,000 shares ($187K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Collins Helen Louise
Role
CHIEF MEDICAL OFFICER
Sold
5,000 shs ($199K)
Approx. gross sale proceeds
$199K
Approx. exercise cost
$12K
Approx. pre-tax spread
$187K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 5,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,000 | $2.48 | $12K |
| Sale | Common Stock | 3,475 | $39.534 | $137K |
| Sale | Common Stock | 1,302 | $40.2473 | $52K |
| Sale | Common Stock | 223 | $41.2052 | $9K |
Holdings After Transaction:
Stock Option (right to buy) — 126,268 contracts (Direct);
Common Stock — 25,000 shares (Direct)
Footnotes (7)
- F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3. This transaction was executed in multiple trades at prices ranging from $38.855 to $39.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4. This transaction was executed in multiple trades at prices ranging from $39.855 to $40.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5. This transaction was executed in multiple trades at prices ranging from $40.8625 to $41.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Key Figures
Shares sold: 5,000 shares
Sale prices: $39.5340, $40.2473, $41.2052 per share
Options exercised: 5,000 shares at $2.4800/share
+4 more
7 metrics
Shares sold
5,000 shares
Total Common Stock sold on May 18, 2026
Sale prices
$39.5340, $40.2473, $41.2052 per share
Weighted-average prices for reported open-market sales
Options exercised
5,000 shares at $2.4800/share
Stock option exercise into Common Stock on May 18, 2026
Shares held after
25,000 shares
Direct Common Stock ownership following reported transactions
Options remaining
126,268 options at $2.4800/share
Stock options outstanding after the exercise
Option expiration
June 17, 2031
Expiration date of the reported stock option grant
Net share change
5,000 net shares sold
NetBuySellShares from transaction summary
Key Terms
Rule 10b5-1 trading plan, restricted stock units (RSUs), weighted average sale price, Stock Option (right to buy), +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The option exercise and sales ... were effected pursuant to a Rule 10b5-1 trading plan adopted ..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units (RSUs) financial
"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
fully vested and exercisable financial
"All of the shares subject to this option are fully vested and exercisable as of the date hereof."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Enliven Therapeutics (ELVN) CMO Helen Collins trade in this Form 4?
Helen Collins reported selling 5,000 shares of Enliven Therapeutics Common Stock and exercising options for 5,000 shares. The trades occurred on May 18, 2026, and involved open-market sales plus a stock option exercise at a $2.4800 per-share exercise price.
What stock options did Helen Collins exercise in the ELVN Form 4?
She exercised a stock option covering 5,000 shares of Enliven Therapeutics Common Stock at a $2.4800 exercise price. Footnotes note that all shares subject to this option were fully vested and exercisable, and the option carries an expiration date of June 17, 2031.
Was the Enliven Therapeutics (ELVN) insider trading done under a Rule 10b5-1 plan?
Yes. A footnote states the option exercise and related sales were effected under a Rule 10b5-1 trading plan. The plan was adopted on October 19, 2025, indicating these transactions were pre-arranged rather than discretionary trades based solely on short-term market conditions.
Does this ELVN Form 4 include any information on restricted stock units (RSUs)?
Yes. Footnotes explain that certain reported securities are restricted stock units, each RSU representing a contingent right to receive one share of Enliven Therapeutics Common Stock. RSUs typically vest over time or upon meeting conditions, then settle into actual shares for the reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates